Boston Scientific shares fell 12.53% to $50.42 after management reiterated soft full-year organic growth guidance and flagged weaker demand in key WATCHMAN and urology franchises. The update points to near-term pressure on core product lines and deteriorating investor sentiment around the company’s growth outlook.
Boston Scientific shares fell 12.53% to $50.42 after management reiterated soft full-year organic growth guidance and flagged weaker demand in key WATCHMAN and urology franchises. The update points to near-term pressure on core product lines and deteriorating investor sentiment around the company’s growth outlook.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
strongly negative
Sentiment Score
-0.55
Ticker Sentiment
